DK1392318T3 - 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse - Google Patents

15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse

Info

Publication number
DK1392318T3
DK1392318T3 DK02720623T DK02720623T DK1392318T3 DK 1392318 T3 DK1392318 T3 DK 1392318T3 DK 02720623 T DK02720623 T DK 02720623T DK 02720623 T DK02720623 T DK 02720623T DK 1392318 T3 DK1392318 T3 DK 1392318T3
Authority
DK
Denmark
Prior art keywords
prostaglandins
keto
drug
treatment
induced constipation
Prior art date
Application number
DK02720623T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23104042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1392318(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK1392318T3 publication Critical patent/DK1392318T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02720623T 2001-05-02 2002-04-26 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse DK1392318T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28772001P 2001-05-02 2001-05-02
PCT/JP2002/004223 WO2002089812A1 (en) 2001-05-02 2002-04-26 Composition for treating drug-induced constipation with 15-keto-prostaglandins

Publications (1)

Publication Number Publication Date
DK1392318T3 true DK1392318T3 (da) 2007-06-25

Family

ID=23104042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02720623T DK1392318T3 (da) 2001-05-02 2002-04-26 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse

Country Status (19)

Country Link
US (1) US6982283B2 (enExample)
EP (1) EP1392318B1 (enExample)
JP (1) JP4332353B2 (enExample)
KR (1) KR100886598B1 (enExample)
CN (1) CN1522147B (enExample)
AR (2) AR035237A1 (enExample)
AT (1) ATE355067T1 (enExample)
AU (1) AU2002251554B2 (enExample)
BR (1) BR0209327A (enExample)
CA (1) CA2444103C (enExample)
DE (1) DE60218451T2 (enExample)
DK (1) DK1392318T3 (enExample)
ES (1) ES2282408T3 (enExample)
MX (1) MXPA03010019A (enExample)
NO (1) NO335143B1 (enExample)
NZ (1) NZ529187A (enExample)
PT (1) PT1392318E (enExample)
TW (1) TWI302100B (enExample)
WO (1) WO2002089812A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
JP4889219B2 (ja) 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
KR101466980B1 (ko) * 2005-04-12 2014-12-01 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자펌프 억제제의 병용
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
WO2009059307A1 (en) * 2007-11-01 2009-05-07 Washington University In St. Louis Compositions and methods for treating pruritus
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US8957024B2 (en) 2011-07-27 2015-02-17 Washington University Composition and methods for reducing opioid-induced pruritus
KR20140052389A (ko) 2012-10-24 2014-05-07 주식회사 아리바이오 해양 심층수 또는 염지하수로부터 제조된 고경도의 미네랄 워터를 포함하는 변비 예방, 개선 또는 치료용 조성물
US20140116916A1 (en) 2012-10-31 2014-05-01 2294719 Ontario Limited Therapy for Constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN105777601A (zh) * 2014-12-26 2016-07-20 中国人民解放军第二军医大学 一种前列地尔衍生物及其药物制剂
JP2019513355A (ja) * 2016-03-29 2019-05-30 コロナリーコンセプツ エルエルシー 便秘症を処置するための製剤
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
EP0310305B1 (en) * 1987-10-02 1992-07-22 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Cathartics
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
DE69130586T2 (de) * 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
BR0209863A (pt) * 2001-05-18 2004-06-08 Sucampo Ag Composição catártica

Also Published As

Publication number Publication date
CN1522147B (zh) 2010-05-12
NZ529187A (en) 2005-10-28
KR20040008168A (ko) 2004-01-28
NO20034864D0 (no) 2003-10-31
CA2444103C (en) 2010-06-08
EP1392318B1 (en) 2007-02-28
WO2002089812A1 (en) 2002-11-14
US20030073746A1 (en) 2003-04-17
ATE355067T1 (de) 2006-03-15
NO20034864L (no) 2003-12-23
JP2004527567A (ja) 2004-09-09
BR0209327A (pt) 2004-07-20
NO335143B1 (no) 2014-09-29
CA2444103A1 (en) 2002-11-14
PT1392318E (pt) 2007-05-31
MXPA03010019A (es) 2004-02-12
ES2282408T3 (es) 2007-10-16
DE60218451D1 (de) 2007-04-12
CN1522147A (zh) 2004-08-18
AR100696A2 (es) 2016-10-26
AR035237A1 (es) 2004-05-05
KR100886598B1 (ko) 2009-03-05
TWI302100B (en) 2008-10-21
JP4332353B2 (ja) 2009-09-16
US6982283B2 (en) 2006-01-03
EP1392318A1 (en) 2004-03-03
AU2002251554B2 (en) 2007-05-24
DE60218451T2 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
IS6971A (is) Ný efnasambönd
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
ATE355067T1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DK1206436T3 (da) Retinoider til behandling af emfysem
DE60211292D1 (de) Differenzdrehmomentbegrenzer
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1503995T3 (da) Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
ITMC20010025U1 (it) Doccia multifunzionale
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
DK1392711T3 (da) Fremgangsmåde til fremstilling af xylose
NO20025765D0 (no) Kombinasjonssett for behandling av malaria